Advertisement

Hepatology International

, Volume 13, Issue 4, pp 407–415 | Cite as

Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers

  • Tsutomu NishidaEmail author
  • Tokuhiro Matsubara
  • Takayuki Yakushijin
  • Masami Inada
Review Article

Abstract

Hepatitis B virus (HBV) reactivation (HBV-R) and hepatitis related to HBV-R are well-recognized complications that occur in patients who have undergone cytotoxic chemotherapy or immunosuppressive therapy. The degree of HBV-R in this population varies from self-limited or asymptomatic hepatitis to acute liver failure, which may lead to life-threatening events. However, no established treatment or standard surveillance method exists for monitoring patients to predict the development of HBV-R during or after chemotherapy or immunosuppressive therapy, particularly regarding resolved HBV infection. Prophylactic antiviral agents and regular monitoring of HBV-DNA levels are known to be useful methods for preventing HBV-R; however, these methods require considerable financial resources, and such resources are limited in the endemic areas of HBV infection. Most patients with resolved HBV infection do not develop a hepatitis flare or self-limited HBV-R with only an increase in HBV DNA. However, some patients may develop HBV-R even 1 year or more after the last chemotherapy treatment. Therefore, predicting the development of HBV-R and its timing is difficult, and exploring markers that could help predict whether or when HBV reactivation occurs is necessary. In this review, we address the predictive risk factors for HBV-R in patients with resolved HBV infection, focusing on the ability of anti-HBs and anti-HBc to predict HBV-R. We conclude that the combination of anti-HBc and anti-HBs titers may be a reliable and useful predictor for managing HBV-R.

Keywords

HBV reactivation Anti-HBs Anti-HBc Resolved HBV infection 

Notes

Author contributions

TN wrote the initial draft of the manuscript. TY, TM and MI critically reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

Tsutomu Nishida, Tokuhiro Matsubara, Takayuki Yakushijin and Masami Inada declare no conflict of interest. The authors alone are responsible for the content and writing of this paper.

References

  1. 1.
    Nishida T, Hiramatsu N, Mizuki M, Nagatomo I, Kida H, Tazumi K, et al. Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatol Res 2013;43(4):339–346.  https://doi.org/10.1111/j.1872-034X.2012.01073.x (Epub 2012/08/14) CrossRefPubMedGoogle Scholar
  2. 2.
    Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68(1):105–112 (Epub 1975/01/01) PubMedGoogle Scholar
  3. 3.
    Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343(8890):142–146 (Epub 1994/01/15) CrossRefPubMedGoogle Scholar
  4. 4.
    Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, de la Pena J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg 1999;5(3):175–183.  https://doi.org/10.1002/lt.500050301 (Epub 1999/05/05) CrossRefPubMedGoogle Scholar
  5. 5.
    Lau JY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989;73(270):911–917 (Epub 1989/10/01) PubMedGoogle Scholar
  6. 6.
    Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131(1):59–68.  https://doi.org/10.1053/j.gastro.2006.04.015 CrossRefPubMedGoogle Scholar
  7. 7.
    European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167–185.  https://doi.org/10.1016/j.jhep.2012.02.010 CrossRefGoogle Scholar
  8. 8.
    Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection—EASL Special Conference. J Hepatol 2015;63(5):1238–1253.  https://doi.org/10.1016/j.jhep.2015.06.026 (Epub 2015/07/08) CrossRefPubMedGoogle Scholar
  9. 9.
    Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148(1):215–219.  https://doi.org/10.1053/j.gastro.2014.10.039 (Epub 2014/12/03) CrossRefPubMedGoogle Scholar
  10. 10.
    Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99(7):2324–2330 (Epub 2002/03/16) CrossRefPubMedGoogle Scholar
  11. 11.
    Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90(7):1306–1311.  https://doi.org/10.1038/sj.bjc.6601699 (Epub 2004/04/01) CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148(1):221–244.  https://doi.org/10.1053/j.gastro.2014.10.038 (Epub 2014/12/03) CrossRefPubMedGoogle Scholar
  13. 13.
    Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560–1599.  https://doi.org/10.1002/hep.29800 (Epub 2018/02/07) CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100(1):182–188 (Epub 1991/01/01) CrossRefPubMedGoogle Scholar
  15. 15.
    Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27(4):605–611.  https://doi.org/10.1200/JCO.2008.18.0182 CrossRefPubMedGoogle Scholar
  16. 16.
    Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116(20):4769–4776.  https://doi.org/10.1002/cncr.25253 CrossRefPubMedGoogle Scholar
  17. 17.
    Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22(5):1170–1180.  https://doi.org/10.1093/annonc/mdq583 (Epub 2010/12/01) CrossRefPubMedGoogle Scholar
  18. 18.
    Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013;49(16):3486–3496.  https://doi.org/10.1016/j.ejca.2013.07.006 (Epub 2013/08/06) CrossRefPubMedGoogle Scholar
  19. 19.
    Matsubara T, Nishida T, Shimoda A, Shimakoshi H, Amano T, Sugimoto A, et al. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection. Oncol Lett 2017;14(6):6543–6552.  https://doi.org/10.3892/ol.2017.7012 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014;32(33):3736–3743.  https://doi.org/10.1200/JCO.2014.56.7081 CrossRefPubMedGoogle Scholar
  21. 21.
    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63(1):261–283.  https://doi.org/10.1002/hep.28156 (Epub 2015/11/14) CrossRefPubMedGoogle Scholar
  22. 22.
    Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6(3):531–561.  https://doi.org/10.1007/s12072-012-9365-4 CrossRefPubMedGoogle Scholar
  23. 23.
    Drafting Committee for Hepatitis Management G, the Japan Society of H. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatology Research 2014;44(Suppl S1):1–58.  https://doi.org/10.1111/hepr.12269 CrossRefGoogle Scholar
  24. 24.
    Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10(1):1–98.  https://doi.org/10.1007/s12072-015-9675-4 CrossRefPubMedGoogle Scholar
  25. 25.
    European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370–398.  https://doi.org/10.1016/j.jhep.2017.03.021 (Epub 2017/04/22) CrossRefGoogle Scholar
  26. 26.
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507–539.  https://doi.org/10.1002/hep.21513 CrossRefPubMedGoogle Scholar
  27. 27.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661–62.  https://doi.org/10.1002/hep.23190 CrossRefPubMedGoogle Scholar
  28. 28.
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22(5):927–934.  https://doi.org/10.1200/JCO.2004.05.161 (Epub 2004/03/03) CrossRefPubMedGoogle Scholar
  29. 29.
    Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015;62(1):40–46.  https://doi.org/10.1002/hep.27716 (Epub 2015/01/24) CrossRefPubMedGoogle Scholar
  30. 30.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46(4):556–564.  https://doi.org/10.1007/s00535-010-0367-5 (Epub 2011/01/20) CrossRefPubMedGoogle Scholar
  31. 31.
    Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis 2013;7(2):113–119.  https://doi.org/10.1016/j.crohns.2012.03.001 (Epub 2012/04/03) CrossRefPubMedGoogle Scholar
  32. 32.
    Organization WH. Hepatitis B. 2018. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed 5 May 2019
  33. 33.
    Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 2004;350(11):1118–1129.  https://doi.org/10.1056/NEJMra031087 CrossRefPubMedGoogle Scholar
  34. 34.
    Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987;126(3):492–499CrossRefPubMedGoogle Scholar
  35. 35.
    Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014;59(6):2092–2100.  https://doi.org/10.1002/hep.26718 CrossRefPubMedGoogle Scholar
  36. 36.
    Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B Virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis 2015;61(5):719–729.  https://doi.org/10.1093/cid/civ344 CrossRefPubMedGoogle Scholar
  37. 37.
    Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, et al. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol 2016;88(6):1010–1017.  https://doi.org/10.1002/jmv.24423 CrossRefPubMedGoogle Scholar
  38. 38.
    Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 2017;66(2):379–388.  https://doi.org/10.1002/hep.29082 (Epub 2017/01/28) CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011;90(10):1219–1223.  https://doi.org/10.1007/s00277-011-1241-0 (Epub 2011/04/27) CrossRefPubMedGoogle Scholar
  40. 40.
    Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008;93(6):951–952.  https://doi.org/10.3324/haematol.12557 (Epub 2008/06/03) CrossRefPubMedGoogle Scholar
  41. 41.
    Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91(7):1007–1012.  https://doi.org/10.1007/s00277-012-1405-6 (Epub 2012/01/26) CrossRefPubMedGoogle Scholar
  42. 42.
    Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, et al. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 2016;44(3):627–638.  https://doi.org/10.1177/0300060516638992 (Epub 2016/04/07) CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Yagci M, Suyani E, Kizil Cakar M. The Impact of chemotherapy on hepatitis B antibody titer in patients with hematological malignancies. Turk J Haematol 2015;32(3):251–256.  https://doi.org/10.4274/tjh.2013.0342 (Epub 2015/09/18) CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Papalopoulos I, Fanouriakis A, Kougkas N, Flouri I, Sourvinos G, Bertsias G, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol 2018;36(1):102–109 (Epub 2017/08/30) PubMedGoogle Scholar
  45. 45.
    Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol 2018;69(2):286–292.  https://doi.org/10.1016/j.jhep.2018.02.033 CrossRefPubMedGoogle Scholar
  46. 46.
    Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986;234(4782):1398–1401CrossRefPubMedGoogle Scholar
  47. 47.
    Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46(1):160–170.  https://doi.org/10.1016/j.jhep.2006.10.007 (Epub 2006/11/23) CrossRefPubMedGoogle Scholar
  48. 48.
    Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998;26(4):895–897 (Epub 1998/06/13) CrossRefPubMedGoogle Scholar
  49. 49.
    Li A, Yuan Q, Huang Z, Fan J, Guo R, Lou B, et al. Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol 2010;17(3):464–469.  https://doi.org/10.1128/CVI.00457-09 (Epub 2010/01/29) CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007;47(7):1197–1205.  https://doi.org/10.1111/j.1537-2995.2007.01276.x (Epub 2007/06/22) CrossRefPubMedGoogle Scholar
  51. 51.
    Caviglia GP, Abate ML, Tandoi F, Ciancio A, Amoroso A, Salizzoni M, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J Hepatol 2018;69(2):301–307.  https://doi.org/10.1016/j.jhep.2018.03.021 (Epub 2018/04/06) CrossRefPubMedGoogle Scholar
  52. 52.
    Seto WK, Wong DK, Chan TS, Hwang YY, Fung J, Liu KS, et al. Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016;111(12):1788–1795.  https://doi.org/10.1038/ajg.2016.436 (Epub 2016/09/21) CrossRefPubMedGoogle Scholar
  53. 53.
    Zoppoli G, Bruzzone B, Caligiuri P, Picciotto A, Balleari E, Bruzzone A, et al. From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients. Br J Haematol 2009;144(6):969–970.  https://doi.org/10.1111/j.1365-2141.2008.07539.x CrossRefPubMedGoogle Scholar
  54. 54.
    Liu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma 2016;57(6):1355–1362.  https://doi.org/10.3109/10428194.2015.1116121 (Epub 2016/01/05) CrossRefPubMedGoogle Scholar
  55. 55.
    Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res 2016;50:46–49.  https://doi.org/10.1016/j.leukres.2016.09.014 (Epub 2016/10/27) CrossRefPubMedGoogle Scholar
  56. 56.
    Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, et al. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res 2015.  https://doi.org/10.1111/hepr.12496 CrossRefPubMedGoogle Scholar
  57. 57.
    Yamada T, Nannya Y, Suetsugu A, Shimizu S, Sugihara J, Shimizu M, et al. Late reactivation of hepatitis B virus after chemotherapies for hematological malignancies: a case report and review of the literature. Intern Med 2017;56(1):115–118.  https://doi.org/10.2169/internalmedicine.56.7468 CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329(25):1842–1847.  https://doi.org/10.1056/NEJM199312163292503 (Epub 1993/12/16) CrossRefPubMedGoogle Scholar
  59. 59.
    Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. ‘EUROHEP’ consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. J Hepatol 1994;21(6):1140–1143 (Epub 1994/12/01) CrossRefPubMedGoogle Scholar
  60. 60.
    Devlin J, Smith HM, O’Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994;21(2):204–210 (Epub 1994/08/01) CrossRefPubMedGoogle Scholar
  61. 61.
    Konig V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58(5):553–559 (Epub 1994/09/15) CrossRefPubMedGoogle Scholar
  62. 62.
    Polak WG, Gladysz A, Rotter K. Prevention of hepatitis B recurrence after liver transplantation. Ann Transplant 2005;10(3):11–16 (Epub 2006/04/19) PubMedGoogle Scholar
  63. 63.
    Wong TC, Fung JY, Cui TY, Lam AH, Dai JW, Chan AC, et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis. J Hepatol 2019.  https://doi.org/10.1016/j.jhep.2019.03.003 (Epub 2019/03/16) CrossRefPubMedGoogle Scholar
  64. 64.
    Lu S, Xu Y, Mu Q, Cao L, Chen J, Zhu Z, et al. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy. Leuk Lymphoma 2015;56:1027–1032CrossRefPubMedGoogle Scholar
  65. 65.
    Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer 2018;13:40CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer 2015;34:225–234PubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyToyonaka Municipal HospitalToyonakaJapan
  2. 2.Department of Gastroenterology and HepatologyOsaka General Medical CenterOsakaJapan

Personalised recommendations